NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
5 hedge funds and large institutions have $45.4K invested in NLS Pharmaceutics Warrant in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0.52% less ownership
Funds ownership: 3.02% → 2.5% (-0.52%)
56% less capital invested
Capital invested by funds: $103K → $45.4K (-$57.5K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$99 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$10 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $28.1K | – | – | – |
|
|
ACM
2
Altium Capital Management
New York
| $11.2K | – | – | – |
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| $5.61K | – | – | – |
|
|
CS
4
Clear Street
New York
| $477 | -$10 | -100 | -1% |
|
|
5
UBS Group
Zurich,
Switzerland
| $55 | +$99 | +1,000 | New |
|
NLSPW Hedge Fund Activity: Q4 2023 in Review
5 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q4 2023, worth a combined $45.4K — down 56% from $103K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NLSPW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $99. The largest seller was Clear Street, cutting an estimated $10.
- 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $45.4K of NLS Pharmaceutics Warrant stock for Q4 2023, down 56% quarter-over-quarter.
- 1 fund opened new NLS Pharmaceutics Warrant positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest NLS Pharmaceutics Warrant buyer in Q4 2023 was UBS Group, an estimated $99 added.
- The largest NLS Pharmaceutics Warrant seller in Q4 2023 was Clear Street, an estimated $10 sold.
Based on aggregated 13F filings for Q4 2023.